Clinical Trials Directory

Trials / Completed

CompletedNCT01625377

A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients

A National, Multi-center, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Everolimus Combined With Enteric-coated Mycophenolate Sodium Compared to the Standard Treatment Combining Tacrolimus and Enteric-coated Mycophenolate Sodium in de Novo Liver Transplant Recipients

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
188 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aims of the study was to evaluate the safety and efficacy of early introduction one month post-transplantation of everolimus associated to EC-MPS with tacrolimus discontinuation in de novo liver transplant recipients and to evaluate if it leads to a better renal function 6 month post-transplantation compared to standard treatment associating tacrolimus and EC-MPS. The renal function was estimated by glomerular filtration rate.

Conditions

Interventions

TypeNameDescription
DRUGtacrolimusArm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
DRUGeverolimusArm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
DRUGBasiliximabBasiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
DRUGMycophenolic AcidDose of 1440 mg/day from transplantation to month 6 post- transplantation
DRUGCorticosteroidsAdministration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice

Timeline

Start date
2012-12-01
Primary completion
2015-03-01
Completion
2015-03-01
First posted
2012-06-21
Last updated
2016-04-27
Results posted
2016-04-27

Locations

14 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01625377. Inclusion in this directory is not an endorsement.